PDCD1 and melanoma: First-line immunotherapy treatment options for patients with advanced melanoma include monotherapy with anti-programmed cell death-1 (Anti-PD-1) antibodies such as nivolumab or pembrolizumab and combination treatment with nivolumab and ipilimumab (a cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody).